NZ712784A - Compositions and methods for topical delivery of prostaglandins to subcutaneous fat - Google Patents

Compositions and methods for topical delivery of prostaglandins to subcutaneous fat

Info

Publication number
NZ712784A
NZ712784A NZ712784A NZ71278414A NZ712784A NZ 712784 A NZ712784 A NZ 712784A NZ 712784 A NZ712784 A NZ 712784A NZ 71278414 A NZ71278414 A NZ 71278414A NZ 712784 A NZ712784 A NZ 712784A
Authority
NZ
New Zealand
Prior art keywords
methods
subcutaneous fat
skin
compositions
prostaglandins
Prior art date
Application number
NZ712784A
Other languages
English (en)
Inventor
Michael S Singer
Murat V Kalayoglu
Original Assignee
Topokine Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50933526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ712784(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Topokine Therapeutics Inc filed Critical Topokine Therapeutics Inc
Priority to NZ730201A priority Critical patent/NZ730201B2/en
Publication of NZ712784A publication Critical patent/NZ712784A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ712784A 2013-05-10 2014-05-09 Compositions and methods for topical delivery of prostaglandins to subcutaneous fat NZ712784A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ730201A NZ730201B2 (en) 2013-05-10 2014-05-09 Compositions and methods for topical delivery of prostaglandins to subcutaneous fat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361822139P 2013-05-10 2013-05-10
PCT/US2014/037512 WO2014183045A2 (en) 2013-05-10 2014-05-09 Compositions and methods for topical delivery of prostaglandins to subcutaneous fat

Publications (1)

Publication Number Publication Date
NZ712784A true NZ712784A (en) 2017-03-31

Family

ID=50933526

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ712784A NZ712784A (en) 2013-05-10 2014-05-09 Compositions and methods for topical delivery of prostaglandins to subcutaneous fat

Country Status (27)

Country Link
US (5) US9040584B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP3395328A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5930568B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (4) KR20200037458A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN109966240A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2014262495B9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015028290A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2907721C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2015003270A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20150652A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1118654T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK3124015T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2670323T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE037405T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL240807A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX347969B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY183193A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2753788T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ712784A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12015502503A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL3124015T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2863886T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2635864C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG10201604659QA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2863886T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014183045A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201507702B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
EP3421030A1 (en) 2009-11-09 2019-01-02 Allergan, Inc. Compositions and methods for stimulating hair growth
EP2982373B1 (en) 2011-01-19 2018-06-13 Topokine Therapeutics, Inc. Methods and compostions for reducing body fat
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
NO2753788T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
US9795615B2 (en) * 2015-04-30 2017-10-24 Allergan, Inc. Methods for fat reduction
US20180118707A1 (en) * 2015-06-09 2018-05-03 Thesan Pharmaceuticals, Inc. Beta-naphthoisoflavones, compositions containing, and uses of, same
US20180179174A1 (en) * 2015-06-23 2018-06-28 Thesan Pharmaceuticals, Inc. 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
WO2016209619A1 (en) * 2015-06-23 2016-12-29 Thesan Pharmaceuticals, Inc. 12h-benzo[a]xanthen-12-ones, compositions containing, and uses of, same
WO2017075289A1 (en) 2015-10-27 2017-05-04 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
CN107773758B (zh) * 2016-08-31 2021-02-26 程辉 一种用于消除皮下脂肪沉积的组合物及其应用
CN112996854B (zh) * 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US10835502B2 (en) 2018-10-16 2020-11-17 Polithera, Inc. Alcohol-based compositions and uses thereof
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
ES2953088T3 (es) * 2019-04-24 2023-11-08 Follicum Ab Formulación tópica
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
JP6855026B1 (ja) * 2020-11-09 2021-04-07 東亜薬品株式会社 タフルプロスト点眼液
WO2023287690A1 (en) * 2021-07-12 2023-01-19 Ocusoft, Inc. Skin moisturizing compositions

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0302147A1 (en) 1987-08-03 1989-02-08 The Procter & Gamble Company Topical tanning compositions
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1224935A3 (en) 1988-09-06 2003-03-26 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5011062A (en) 1990-05-09 1991-04-30 Delco Electronics Corporation Ultrasonic welding mask
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH07138258A (ja) 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
RU2157689C2 (ru) 1996-07-24 2000-10-20 Панацея Биотек Лтд. Фармацевтические композиции терапевтического антивоспалительного и болеутоляющего средства для местного нанесения и способ их получения
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
JP4397973B2 (ja) 1997-02-04 2010-01-13 ジョンストン， マーレイ エイ． 瞼の毛髪の成長を刺激するための局所的組成物
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
WO1999032441A1 (en) 1997-12-22 1999-07-01 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
WO2001058240A2 (en) 2000-02-10 2001-08-16 Massachusetts Eye And Ear Infirmary Photodynamic therapy for treating conditions of the eye
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
WO2002080860A2 (en) 2001-03-27 2002-10-17 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
GB0202159D0 (en) 2002-01-30 2002-03-20 Sensor Highway Ltd OPtical time domain reflectometry
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
JP4387639B2 (ja) * 2002-07-16 2009-12-16 久光製薬株式会社 経皮吸収製剤
US6864282B2 (en) 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
US20040115234A1 (en) 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
CA2502439C (en) 2002-10-23 2011-11-22 Sucampo Ag Prostaglandin compounds for the treatment of obesity
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
BRPI0408454A (pt) 2003-03-21 2006-04-04 Nexmed Holdings Inc composição tópica, método de tratar a ejaculação precoce, e, uso da composição
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050058614A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
PT1758590E (pt) 2004-05-19 2011-11-15 Univ California Utilização de um detergente para a remoção não cirúrgica de gordura
DE602004017477D1 (de) 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
EP1848541A4 (en) 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR THE OPHTHALMIC ADMINISTRATION OF PHARMACEUTICAL ACTIVE SUBSTANCES
SI1864666T1 (sl) 2005-03-31 2012-10-30 Asahi Glass Co Ltd Zaščitno sredstvo za retinalno nevronsko celico, vsebujoče derivat prostaglandina F2 alfa kot učinkovino
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
WO2007011846A2 (en) * 2005-07-18 2007-01-25 Soundquest, Inc. In-ear auditory device and methods of using same
EP2452686A3 (en) 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US9393218B2 (en) 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
RU2325912C1 (ru) * 2006-09-06 2008-06-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция противовоспалительного и антимикробного действия в форме мази на гидрофобной основе для лечения кожных заболеваний (варианты)
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2008120249A1 (en) * 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
US20100074857A1 (en) * 2008-09-23 2010-03-25 Pamela Lipkin Compositions and methods to treat epithelial-related conditions
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CN101427993A (zh) 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 前列腺素微乳凝胶制剂及其制备方法
EP2228058A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP3421030A1 (en) 2009-11-09 2019-01-02 Allergan, Inc. Compositions and methods for stimulating hair growth
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
WO2012068515A2 (en) 2010-11-18 2012-05-24 Steven Yoelin Compositions and methods for hair growth
WO2013172838A1 (en) 2012-05-17 2013-11-21 Steven Yoelin Compositions and methods for hair growth
EP2982373B1 (en) 2011-01-19 2018-06-13 Topokine Therapeutics, Inc. Methods and compostions for reducing body fat
RU2599249C2 (ru) 2011-02-14 2016-10-10 Аллерган, Инк. Композиции и способы применения сложноэфирных производных биматопроста
US20120251613A1 (en) 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
JP2012250950A (ja) * 2011-06-06 2012-12-20 Santen Pharmaceut Co Ltd アデノシン誘導体とプロスタグランジン類の組合せ剤
RU2014103544A (ru) * 2011-07-20 2015-08-27 Аллерган, Инк. Комбинация фиксированных доз биматопроста и бримонидина
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
KR20140043562A (ko) 2012-09-24 2014-04-10 한국콜마주식회사 무복계면 라타노프로스트 및 그 제조방법
CA2869676C (en) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
NO2753788T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2013-05-10 2018-06-16
US9820993B2 (en) * 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen

Also Published As

Publication number Publication date
PL2863886T3 (pl) 2017-03-31
AU2014262495B9 (en) 2019-07-25
EP2863886A2 (en) 2015-04-29
MX2015015535A (es) 2016-02-09
US20150105462A1 (en) 2015-04-16
KR101651450B1 (ko) 2016-08-26
US20150231251A1 (en) 2015-08-20
CA2907721A1 (en) 2014-11-13
US9849179B2 (en) 2017-12-26
CN105209015B (zh) 2018-11-20
PT2863886T (pt) 2016-12-02
CN109966240A (zh) 2019-07-05
US20200282059A1 (en) 2020-09-10
ES2604160T3 (es) 2017-03-03
WO2014183045A3 (en) 2015-01-29
BR112015028290A2 (pt) 2017-07-25
NZ730201A (en) 2021-01-29
CL2015003270A1 (es) 2016-07-08
RU2635864C2 (ru) 2017-11-16
NO2753788T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-06-16
KR20160102326A (ko) 2016-08-29
JP2016518416A (ja) 2016-06-23
IL251448B (en) 2021-01-31
KR102098987B1 (ko) 2020-04-08
PH12015502503B1 (en) 2016-02-22
KR20210040180A (ko) 2021-04-12
JP5930568B1 (ja) 2016-06-08
WO2014183045A2 (en) 2014-11-13
IL240807A (en) 2017-04-30
RU2015141767A (ru) 2017-04-06
AU2014262495A1 (en) 2015-10-22
MY183193A (en) 2021-02-18
EP3124015A1 (en) 2017-02-01
DK2863886T3 (en) 2016-12-12
US9040584B2 (en) 2015-05-26
ZA201507702B (en) 2016-11-30
MX2020002881A (es) 2020-07-22
KR20200037458A (ko) 2020-04-08
US20220152206A1 (en) 2022-05-19
CN105209015A (zh) 2015-12-30
KR20150133865A (ko) 2015-11-30
SG11201600068WA (en) 2016-02-26
CA2907721C (en) 2016-02-23
AU2014262495B2 (en) 2019-07-18
CR20150652A (es) 2016-06-01
MX347969B (es) 2017-05-18
PH12015502503A1 (en) 2016-02-22
EP3124015B1 (en) 2018-03-28
CY1118654T1 (el) 2017-07-12
SG10201604659QA (en) 2016-07-28
PT3124015T (pt) 2018-05-10
ES2670323T3 (es) 2018-05-30
HUE037405T2 (hu) 2018-08-28
JP2016135810A (ja) 2016-07-28
HUE030977T2 (en) 2017-06-28
EP3395328A1 (en) 2018-10-31
US10556012B2 (en) 2020-02-11
AU2021221900A1 (en) 2021-09-23
DK3124015T3 (en) 2018-06-06
HK1213200A1 (zh) 2016-06-30
AU2019250230A1 (en) 2019-11-07
EP2863886B1 (en) 2016-08-24
IL251448A0 (en) 2017-05-29
SI2863886T1 (sl) 2017-01-31
PL3124015T3 (pl) 2018-09-28
US20180200372A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
MX2020002881A (es) Composiciones y metodos para el suministro topico de prostaglandinas a la grasa subcutanea.
MX338746B (es) Vitamina d3 y analogos de la misma para tratar alopecia.
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
MY192033A (en) Method of dosing and use of soft anticholinergic esters
BR112012010083B8 (pt) Composição farmacêutica tópica de liberação sustentada e uso relacionado
NZ703808A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
PE20140936A1 (es) Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas
NZ716034A (en) Treatment of inflammatory lesions of rosacea with ivermectin
EP4552650A3 (en) Methods and compositions for treatment of skin
BR112014016661A8 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
NZ706990A (en) A veterinary method of alleviating noise aversion
PH12015502073A1 (en) Pharmaceutical composition for the treatment of fungal infections
WO2012135812A3 (en) Treatment for dermatological pathologies
WO2014178789A9 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
IN2015DN01329A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2013028904A3 (en) Dermal filler compositions including antioxidants
MX2014014818A (es) Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel.
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
BR112015019524A2 (pt) tratamento de combinação
WO2014183018A3 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES THROUGH INHIBITING TGF-β ACTIVITY
CU20130004A7 (es) Agentes terapéuticos 976
BR112014019442A8 (pt) Composição injetável contendo fosfatidilcolina desprovida de deoxicolato de sódio e seu método de preparação
MX378095B (es) Emulsion de aceite en agua
WO2012095500A3 (en) Pharmaceutical compositions for the treatment of parasitic diseases, cancer, or skin diseases by topical administration
WO2012068169A3 (en) Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2019 BY COMPUTER PACKAGES INC

Effective date: 20180418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2020 BY COMPUTER PACKAGES INC

Effective date: 20190418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2022 BY COMPUTER PACKAGES INC

Effective date: 20210418

LAPS Patent lapsed